Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps: Cove Energy, Synairgen, Wilmington...

Mon, 17th May 2010 13:02

PR specialist Freshwater cut the dividend as profits fell to £32,000 from £106,000 in the six months to end February. Revenues fell to £3.66m from £4.51m."While the economic environment remains challenging, Freshwater is seeing greater stability and growth potential in most of its markets. Alongside this, the measures we have taken to cut costs have restored EBITDA operating margins to double-digit percentages in the second quarter and this is continuing in the third quarter," it said.Star Aim-listed oil explorer Cove Energy posted a loss of $1.65m, up from $546,000, as it funded its so far very successful drilling programme. Going forward, Cove says that following the success at Windjammer, the offshore partners requested the Mozambique authorities to change the drilling commitment to 6 deepwater wells. This request has been granted. Drilling of these 6 deepwater wells will continue in 2010 through to 2011 and will be followed by an appraisal programme. In Tanzania, it is working with its partners to commercialise the full gas production potential of the Mnazi Bay gas fields. Drug developer Synairgen says data from SNG001, its inhaled interferon beta product, in a new model of influenza shows for the first time that it can prevent the spread of infection from cell to cell, even after an influenza infection has taken hold. "This is potentially an important breakthrough in the treatment of flu virus infection rather than its prevention. This represents an exciting new development opportunity for our inhaled interferon beta product that extends beyond the existing opportunities identified for asthma and COPD," chief executive Richard Marsden added.Publisher Wilmington has decided the time is now right to invest in overseas expansion in the banking and finance sector and in deeper content and enhanced technology. It expects to invest up to £2m over the next 12 months and to see returns in the financial year ending June 2012 and beyond. Since February, "the trading performance of the group has been in line with our expectations," it said, with trading still very tough in the legal business.
More News
22 Jul 2015 10:44

AstraZeneca starts next phase of testing on Synairgen asthma drug

(ShareCast News) - Synairgen announced AstraZeneca started another phase of testing on its asthma drug. AIM listed Synairgen said AstraZeneca begun its Phase IIa trial of the drug AZD9412 and expected results in early 2017. AstraZeneca would test 220 asthma patients whose conditions were exacerbate

Read more
22 Jul 2015 07:00

Synairgen Says AstraZeneca Begins Phase IIa Trial In Severe Asthma

Read more
22 Jun 2015 07:28

LONDON BRIEFING: Stocks Surge On Optimism For Greek Debt Deal

Read more
22 Jun 2015 05:13

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 15:14

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 05:21

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 15:06

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 05:27

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 14:56

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 15:03

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
15 Jun 2015 14:52

AGM, EGM Calendar - Week Ahead

Read more
3 Mar 2015 08:38

Synairgen Swings To 2014 Pretax Profit On AstraZeneca Licence Deal

Read more
21 Oct 2014 08:50

Tuesday broker round-up UPDATE

African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating. Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy reco

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.